[IP] Third-party payers fail to respect the endocrinologist as a specialist
During my conversations, I have never been asked if I was an endocrinologist
or a specialist. With other specialties, third-party payers utilize the
expert's opinions; eg, only an orthopedist or a neurologist may have the
ability to order procedures such as MRIs with many third-party payers.
Patients with diabetes usually do not consult with an endocrinologist unless
their diabetes is poorly controlled or complications, such as hypoglycemia,
are occurring with their current medications. Because of this, as experts in
the field, we more often have to utilize the newer and more expensive drugs
in these more complex patients.
However, when I call for an approval for my patient to have one of these
newer agents I am treated by the pharmacy technicians employed by
third-party payers as a non-specialist. Invariably, a negative decision is
given based on the criteria provided to these technicians, and although
there is an "appeal process," I have never once been able to talk to a
health care professional (nurse, pharmacist or physician) to make my case
and/or voice my concern. Often, the only way for the patient to obtain his
medication is for the patient and not the endocrinologist to appeal the
/10_3928_1081_597x_20140101_01_1332840/Bell_David.jpg> David S.H. Bell
David S.H. Bell
Who are these technicians who have no knowledge of or disregard my abilities
and qualifications and who have the power to negatively affect the health of
our patients? They are usually not college graduates, have little or no
medical or scientific background, do not earn a high hourly rate and are
usually certified after a 6-week course followed by a test.
Continuous subcutaneous insulin infusion approvals
Third-party payers fail to respect the endocrinologist as a specialist
* Endocrine Today, February 2014
David S.H. Bell, MD
As a solo practitioner with limited ancillary help, I have to deal directly
with third-party payers when a prior authorization is needed to obtain a
drug that - in my opinion - is necessary for a patient with diabetes.
Third-party payers, by and large, approve continuous subcutaneous insulin
infusion (CSII), or insulin pump therapy, prescribed often inappropriately
for patients with type 2 diabetes by primary care physicians and without the
input of an endocrinologist. This is counterintuitive because unlike type 1
diabetes, there has never been a study that demonstrated CSII's superiority
over standard insulin therapy or even combination insulin and oral therapy
in the patient with type 2 diabetes.
A lot of time and effort in endocrine training programs is devoted to
training fellows to be competent in the initiation and maintenance of CSII
therapy. The PCP is not trained in CSII and therefore should not be entitled
to prescribe or participate in the management of CSII. Often, the initiation
of CSII is performed by nurses with the basal rates and bolus insulin
dosages that are initially calculated and prescribed by a nurse on a single
initial visit. These rates and dosages are often never changed.
However, it should be recognized that if CSII therapy was only prescribed by
endocrinologists for patients with type 1 diabetes, sales, profits and the
number of pump company sales representatives would all shrink dramatically.
Therefore, by approving CSII prescribed by a PCP without the input of an
endocrinologist, third-party payers are not only increasing both the cost
and the risk of treating patients with diabetes, but also are once again
ignoring the qualifications expertise and training of an endocrinologist.
Recognition would bring mutual benefit
When the third-party payers finally recognize that endocrinologists are
experts in their field, experts who in most cases should simply be able to
state that, in their opinion, the medication(s) or devices that they
prescribe are necessary, and those third-party payers respect this opinion,
the patient and everyone else will be better served. In addition, if
third-party payers would recognize that the expertise and training of
endocrinologists is essential for the selection of patients for CSII and
that CSII therapy should only be managed by an endocrinologist, significant
savings will accrue.
By recognizing the education, training and skills of an endocrinologist, the
third-party payers should develop a mutually beneficial relationship with
the endocrinologist, a relationship that will result not only in better
health and clinical outcomes for our patients, but also cost containment.
Disclosure: Bell reports no relevant financial disclosures.
[demime 1.01d removed an attachment of type image/jpeg which had a name of
for HELP or to subscribe/unsubscribe/change list versions,
Follow us at https://www.twitter.com/insulinpumpers
Make a long URL short at http://type1.org